CymaBay Therapeutics Inc. (NASDAQ:CBAY) is reporting third quarter earnings results on Thursday 5th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.17 per share.
For the full year, analysts predict loss of $ 0.72 per share.
Stock Performance
Shares of CymaBay Therapeutics Inc. traded low $ -0.10 or -1.20 percent on Wednesday, reaching $ 8.23 with volume of 809.00 thousand shares. CymaBay Therapeutics Inc. has traded high as $ 8.76 and has cracked $ 8.11 on the downward trend
The closing price of $ 8.23, representing a 588.43 % increase from the 52 week low of $ 1.21 and a 8.06 % decrease over the 52 week high of $ 9.06.
The company has a market capital of $ 566.94 million and is part of the Healthcare sector and Biotechnology industry.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease.
